Nihon Chouzai Co., Ltd.
3341.TUnlisted companyNihon Chouzai Co., Ltd. in brief
Nihon Chouzai Co., Ltd. is an unlisted company in the Pharmaceutical industry, based in Japan. It was founded in 1980. In the year to Mar 2021 it had sales of $2.6 B and a net profit of $33 M, about 1 cents of profit for every dollar of sales.
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
Nihon Chouzai Co., Ltd. timeline
- 1980
- 🏁· approximateFounded
- 2005
- ⊕· approximateNihon Generic became a subsidiary
- 2006
- 🔔Initial public offering on Tokyo Stock Exchange as 3341
- 2013
- ⊕· approximateChoseido Pharmaceutical became a subsidiary
- 2024
- 📍· approximateHeadquarters moved to Shiba
Events of Nihon Chouzai Co., Ltd. from Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Nihon Chouzai Co., Ltd.
- Acquisitions and changes
- No longer listed: it is not in the Japan Exchange Group's list of issues listed on the Tokyo Stock Exchange (checked 14 November 2026).
Market cap history
World rank over time
Rank in Japan: #1,095 (Jan 2020) · #1,191 (Jan 2021) · #1,246 (Jan 2022) · #1,304 (Dec 2022) · #1,399 (Jul 2023) · #1,322 (Jan 2024)
Annual results
- Revenue
- $2.6 B
- Operating income
- —
- Net income
- $33 M
Mar-2021 ending year
Acquisitions and funding#
1 acquisitions
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Choseido Pharmaceutical | Apr 2013 | — | — | — | Wikidata |
How Nihon Chouzai Co., Ltd. compares in Pharmaceutical
- Revenue$2.6 B · higher than 80% of 329
- Net margin1.3% · higher than 30% of 315
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Nihon Chouzai Co., Ltd.🇯🇵 | $295 M | — | 1.3% | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
How current the figures are
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- Mar-2021 ending year
- Balance sheet:
- Mar-2021 ending year
- Profile updated:
- Nov 14, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Nihon Chouzai Co., Ltd.? Verify and update this profile — free
Show Nihon Chouzai Co., Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.